Quotient Clinical is the latest CRO snapped up by private equity

U.K. CRO Quotient Clinical is now the property of private equity outfit Bridgepoint Development Capital, joining the crowd of pharma contractors signing up to be acquired in a fast-consolidating industry.

Oxygen Bio taps Duke's in-house CRO to run Phase III for its cardio drug

Duke University leads the way among schools with on-campus CROs, and now Oxygen Biotherapeutics has entrusted the institution with handling late-stage studies of its promising heart drug.

Sluggish Parexel could be poised for a long-term turnaround

Parexel International startled investors last quarter when its net new business dropped 30% from the previous three months.

Pfizer's unlocked trial data could be a boon to CROs

Pfizer has joined the list of Big Pharmas caving to public pressure and opening up their data vaults, and that could mean a valuable trove of study results for CROs plotting new trials--assuming the drugmaker feels like sharing.

Charles River recruits Sloan-Kettering CEO to bolster its science

Charles River Laboratories has convinced the CEO of Memorial Sloan-Kettering Cancer Center to join its board of directors, leading a new committee to ensure the CRO stays on the cutting edge of science.

Venn snags an Irish CRO in its global buyout push

European CRO Venn Life Sciences is back at the buyer's table, picking up Ireland's Medevol in a deal worth just over $1 million.

Fast-growing Agilux doubles its preclinical space

Massachusetts CRO Agilux Laboratories has expanded its in vivo pharmacokinetics footprint, boosting its ability to run preclinical drug-response tests for a growing list of clients.

Sarah Cannon buys a clinical trial outfit to expand its cancer reach

CRO Sarah Cannon Research Institute has acquired Connecticut's Clinical Development Group, a trial consulting outfit with a wide range of offerings in oncology R&D.

Parexel: Strategic partnerships are the future

The transactional model that once accounted for all CRO business is rapidly losing steam, Parexel International tells Outsourcing-Pharma, as Big Pharma sponsors recognize the benefits of deeper-seated strategic partnerships

Analyst: Pharma R&D cuts won't hamper big CROs

Global R&D spending is unlikely to grow by much more than single digits over the next 5 years, but that won't do much harm to the world's biggest CROs, according to a Morningstar analyst, as the industry's heavyweights are only digging deeper into the operations of their sponsors.

Aptuit snags ex-Icon exec to serve as CEO

CRO Aptuit has named Jonathan Goldman as its next CEO, recruiting a veteran from rival Icon and rounding out its executive suite after months of shakeups.

Almac banks $9M in diagnostics deal with Genomic Health

Contract developer Almac has signed a deal to license its technology to Genomic Health for breast cancer diagnostics, reaping $9 million with the chance for a bigger payday down the road.

CRO SillaJen eyes $150M deal for ex-sponsor

As CROs around the world weigh the benefits of developing their own therapies, South Korea's SillaJen has signed a deal worth up to $150 million to acquire former client Jennerex and inherit the company's Phase III-ready cancer vaccine.

Evoke picks SynteractHCR to helm PhIII for diabetes drug

Fresh off a $25 million IPO, Evoke is riding into Phase III with its gastroparesis-treating nasal spray, and now the biotech has recruited SynteractHCR to serve as its go-to CRO for the late-stage effort.

After $2.6B deal, JLL targets more CMOs

Private equity outfit JLL Partners bet big on contract manufacturing last week with its $2.6 billion deal to combine Dutch Royal DSM with its portfolio CMO Patheon, and the fund's co-founder said the company's not done yet.

Indian CROs leap into U.S. with joint venture

Three of India's biggest CROs are joining forces to cash in on U.S. demand for outsourced drug services, launching a combined venture called Axcellerate Pharma.

Pharmacyclics, J&J pick Catalent for blockbuster cancer drug

Pharmacyclics and Johnson & Johnson are riding high on an accelerated approval for the blockbuster hopeful Imbruvica, and now they've tapped Catalent to aid in commercial manufacturing and ongoing clinical trials for the cancer drug.

ResearchDx reaches into India for contract diagnostics work

Contract diagnostics outfit ResearchDx is making its way into India, counting on the boom in companion tests to drive demand for its services around the globe.

Covance taps NeoGenomics for cancer trial diagnostics

Global CRO Covance has struck up a deal to expand its diagnostics capabilities in oncology trials, partnering with NeoGenomics to bolster its anatomic pathology and specialty lab testing.

Vietnam taps Quintiles to up its stake in global trials

The Vietnamese government is looking to boost its share of the world's clinical research market, signing a deal with CRO giant Quintiles to get the ball rolling.